Services on Demand
- Cited by SciELO
- Access statistics
- Cited by Google
- Similars in SciELO
- Similars in Google
Print version ISSN 0034-7094
On-line version ISSN 1806-907X
Rev. Bras. Anestesiol. vol.59 no.3 Campinas May/June 2009
Central pontine myelinolysis after liver transplantation: is sodium the only villain? Case report*
Mielinólisis pontina central después del transplante hepático: ¿es el sodio el único villano? Relato de caso
Bruno Salomé de Morais, TSA, M.D.I; Fabiano Soares Carneiro, TSA, M.D.I; Rodolfo de Morais Araújo, M.D.II; Guilherme Freitas Araújo,M.D.III; Rodrigo Bernardes de Oliveira, M.D.IV
do Hospital Lifecenter e do Grupo de Transplante de Órgãos do
IIME3 do CET de Anestesiologia do Hospital das Clínicas da UFMG
IIIGraduando em Medicina pela UFMG; Acadêmico da Iniciação Científica
IVAnestesiologista do Grupo de Transplante de Órgãos do HC/UFMG; Anestesiologista do Hospital Vila da Serra; Anestesiologista e Coordenador da Residência de Anestesiologista do Hospital Semper
OBJECTIVES: Critically ill patients frequently develop neurologic symptoms,
which frequently become a clinical challenge. Described approximately 50 years
ago, pontine neuronal demyelination is a pathologic change associated with neurologic
and psychiatric problems after liver transplantation. The objective of this
report was to present a case of central pontine myelinolysis diagnosed after
liver transplantation and to discuss its pathophysiology.
CASE REPORT: A 29 years old female patient underwent liver transplantation for fulminant hepatic failure. Postoperatively, she developed neurologic symptoms characteristic of the Locked In Syndrome and the MRI showed changes compatible with central pontine myelinolysis. The patient did not develop dramatic changes in sodium plasma levels, which is frequently incriminated as the causal agent, and improved considerably within a few weeks.
CONCLUSIONS: The etiology of central pontine myelinolysis is multifactorial, and special attention should be given to the group of patients at greater risk, such as those with sudden changes in the plasma levels of sodium, liver transplantation, chronic alcoholics, and malnourished. It is important to recognize that osmotic demyelination can develop in patients with low, normal, or elevated plasma levels of sodium, indicating the contribution of other trigger factors.
Keywords: COMPLICATIONS: central pontine myelinolysis; SURGERY, Transplantation: liver.
Y OBJETIVOS: El aparecimiento de síntomas neurológicos en
pacientes gravemente enfermos es común y muchas veces, es un reto propedéutico.
Descrita hace cerca de 50 años, la desmielinización de las neuronas
de la región pontina, es una alteración patológica asociada
a cuadros neurológicos y psiquiátricos posteriores al transplante
hepático. El objetivo de este relato, fue presentar la mielinólisis
pontina central diagnosticada en el postoperatorio de transplante hepático
y discutir su fisiopatología.
RELATO DEL CASO: Paciente del sexo femenino, 29 años, sometida a transplante hepático debido a un fracaso hepático fulminante. En el postoperatorio, presentó un cuadro neurológico característico de Síndrome Locked In y lesiones compatibles con la mielinólisis pontina central a la resonancia nuclear magnética. La paciente no presentó oscilaciones exageradas del sodio plasmático, que es el ión frecuentemente acusado de ser el agente causador, y evolucionó con una mejoría significativa en algunas semanas.
CONCLUSIONES: La mielinólisis pontina central tiene una etiología multifactorial, y una atención especial debe dársele al grupo de pacientes con mayor riesgo, tales como los sometidos a alteraciones abruptas de la natremia, transplantados de hígado, etilistas crónicos y desnutridos. Es importante reconocer, que los síndromes de desmielinización osmósticos pueden surgir en pacientes con niveles séricos de sodio bajo, normal o elevado, evidenciando la contribución de otros factores desencadenantes.
Central pontine myelinolysis (CPM) is a rare and severe neurologic complication characterized by acute central pontine neuronal demyelination along with severe and occasionally irreversible manifestations 1. Although it is believed that fast correction of the plasma levels of sodium is the main cause 2, this report supports the presence of other factors related to the development of CPM.
This is a 29-year old female, 1.65 m, 58 kg, MELD 40, who underwent orthotopic liver transplantation from a dead donor by reason of a fulminant liver failure. The patient was transferred to the ICU intubated and on mechanical ventilation for 48 hours due to worsening of her neurologic condition and hemodynamic instability.
The patient was monitored with electrocardiogram, pulse oximeter, intra-arterial blood pressure, pulmonary artery catheter with continuous measurements of the cardiac output and mixed venous oxygen saturation. Thromboelastography, erythrogram, coagulogram, blood electrolytes, and arterial blood gases were done periodically during the surgery. She was maintained with balanced general anesthesia and continuous infusion of noradrenaline to maintain mean arterial pressure above 60 mmHg. Ringer's lactate, 5% albumin, and blood products were administered according to the results of serial exams. The patient evolved with hemodynamic stability and transplant viability. She was extubated 48 hours after the transplant, when she developed neurologic changes with quadriplegia and anarthria. She followed movements with horizontal eye movements, but she did not followed commands, and Babinski sign was positive bilaterally. After 24 hours, and magnetic ressoance imaging (MRI) of the head showed central pontine demyelination (Figure 1), confirming the diagnosis of CPM. The patient recovered in a few weeks, being discharged from the hospital with mild dysarthria and dysmetria. She presented good recovery of the muscle strength and was walking normally. Neurologic follow-up continued throughout the postoperative period. During the entire perioperative period, the patient did not develop sudden changes in the plasma levels of sodium, as shown in Table I.
Neurologic complications are frequent after liver transplantation, with an incidence between 8% and 47% 1,3-8. Those complications, which include encephalopathies, cerebrovascular disorders, infections, immunosupressor-induced neurotoxicity, and peripheral nerve lesions can influence considerably survival and quality of life of patients 1.
Central pontine myelinolysis was first described in 1959 9 and in 1978 reported after liver transplantation 10. It has an incidence that ranges from 1.2% to 10% in liver transplant recipients, with a high mortality rate 8,11. By definition, it is a non-inflammatory, frequently symmetrical central pontine demyelination. However, in 10% of the cases demyelination also affects extra-pontine areas, and the term osmotic demyelination syndrome (ODS) was proposed for such cases 2,12. Osmotic demyelination syndromes are rapidly progressive and usually fatal. Central pontine myelinolysis is the most severe post-liver transplantation neurologic complication with a mortality rate higher than 50% in the first two weeks and 90% in six months. When patients survive most of them have neurologic deficits 13-15.
The etiology of osmotic demyelination is not well understood. Although rapid correction of serum sodium levels in hyponatremia have been implicated as the main cause, alcohol abuse and liver transplantation are strong independent risk factors 16. Other risk factors such as adrenal insufficiency, mal nutrition, chronic renal failure and hemodialysis, sepsis, and neoplasms are being identified and it can develop in the absence of fluctuations in sodium serum levels 17,18. Central pontine myelinolysis is a clinical syndrome characterized by quadriplegia and pseudobulbar paralysis, and it is frequently associated with loss of consciousness 19. Progressive lethargy, quadriparesis, dysarthria, ophthalmoplegia, dysphasia, ataxia, and changes in reflexes develop two to seven days after the onset of the treatment of the underlying disease or correction of hydrolelectrolytic imbalance 12. As a consequence, a typical pseudocoma, also known as the locked-in syndrome (quadriplegia, anarthria, a capacity to follow the examiner with the eyes but not to follow command, bilateral Babinski sign) develops 19. Although it can be reversible the patient usually dies after several days or weeks 19.
Radiological confirmation is necessary to exclude other diagnosis and to determine the exact extension of the demyelination. Computed tomography can underestimate the real extension of the disease. Magnetic resonance imaging plays a fundamental role in the determination of the number and extension of the lesions showing acute, symmetrical demyelinating lesions, with hypointensity in T1 and hyperintensity in T2 in the subacute phase due to microhemorrhages secondary to endothelial damage. Lesions are visible on MRI a few days or weeks after the onset of the symptoms 15.
Osmotic demyelinating syndromes are characterized by the dissolution of myelin shafts, sparing the axons. Surprisingly, inflammation is absent suggesting that cell death is by apoptosis 2. Glial cells vulnerable on CPM play an important role in controlling the extracellular osmolality of the neurons they support using glucose as a metabolic substrate. During hyponatremia, in an attempt to reduce cellular edema, cells expel osmotically active particles such as taurine to reduce the amount of intracellular water 16. In the reverse process, glial cells activate Na+-K+ATPase pumps to import electrolytes at the expense of a high metabolic cost using all glucose available 16. This metabolic stress results in the release of glutamate and other excitatory modulators that cause the opening of calcium channels, which, along with the increased production of free radicals by the mitochondria, start the process of apoptosis 16. In patients with liver failure, glial cells do not have adequate glucose or glycogen supply and, therefore, small derangements lead to energy depletion and cell death 2. Organic osmolytes protect the brain from sudden changes in serum osmolality. Patients with liver disease have a deficiency of myo-inositol, an important osmolyte, becoming susceptible to CPM. Besides, those patients present negative nitrogen balance decreasing the amount of amino acids available to form essential organic osmolytes (taurine, creatine) 8. Hypocalcemia represents an additional risk factor because it increases the action potential against which ATPAse has to work 16. Animal models demonstrated that brain levels of phosphocreatine, creatine, myo-inositol, glycerophosphorylcholine, taurine, glutamate, and glutamine decrease 24 hours after the beginning of hyponatremia, but accumulate again slowly during corrective treatment independently of the rate of correction of sodium levels. This explains why normal sodium levels do not exclude the diagnosis of ODS 15.
Osmotic demyelinating syndromes have a predilection for the pons because in this structure neurons and glial cells are arranged in a strict linear configuration forcing cells to lose more osmolytes as an adaptive mechanism, since they cannot become edematous. This set up also limits glucose storage and transportation due to greater metabolic needs and worse perfusion, since it is done only by perforating branches of the basilar artery.
Specific treatments capable of interrupting or reverting the progress of ODS do not exist. Although isolated reports that corticosteroids, thyrotropin releasing hormones, and plasmapheresis 12,20 can be useful, those treatments need more support, since there are no randomized studies proving their efficacy. Several guidelines 11,15,16,21 on adequate sodium administration to hyponatremic patients have been published and one should avoid raising it above 12 mEq.L-1 in the first 24 hours. A proper approach would be to administer 0.5 to 1.0 mEq.L-1.h-1 without exceeding sodium levels of 130 mEq.L-1 in the first 48 hours. Although the patient presented here did not develop important hyponatremia, sodium changes were lower than 10 mEq.L-1 in 24 hours throughout hospitalization. Recommendations on treating individuals with normal serum levels are lacking.
Currently, treatment consists basically on preventing osmotic demyelination. The predominating view (based mainly on case reports) is that individuals with one or more risk factors (severe systemic disease, alcoholism, liver transplantation, malnutrition) should undergo frequent neurological exams, along with imaging exams. The diagnosis of osmotic demyelinating syndrome should be considered in patients who do not recover as expected from a severe disease or in patients who develop new psychiatric symptoms after being severely ill.
Avoiding metabolic stress with administration of thiamine and if necessary slow correction of the serum levels of sodium are recommended in high-risk patients. Strict control of glucose levels, preoperative dialysis in patients with renal failure, and correction of electrolytes levels and other exacerbating factors are recommended 2.
Central pontine myelinolysis has a multifactorial etiology, partly related to neuronal and glial osmotic stress, and partly to deficiencies on glial/neuronal energy supply and use culminating in the process of cellular apoptosis 16. Slow correction of chronic hyponatremia is fundamental for the prevention of this disorder; however, special attention should be given to the group of patients with higher risk factors like liver transplantations, alcoholism, and mal nutrition. It is important to recognize that ODS can affect patients with low, normal, or elevated serum levels of sodium.
01. Kim BS, Lee SG, Hwang S et al. - Neurologic complications in adult living donor liver transplant recipients. Clin Transplant 2007; 21:544-547. [ Links ]
02. Huq S, Wong M, Chan H et al. - Osmotic demyelination syndromes: central and extrapontine myelinolysis. J Clin Neurosci 2007;14:684-688. [ Links ]
03. Lewis MB, Howdle PD - Neurologic complications of liver transplantation in adults. Neurology 2003;61:1174-1178. [ Links ]
04. Lopez OL, Estol C, Colina I et al. - Neurological complications after liver retransplantation. Hepatology 1992;16:162-166. [ Links ]
05. Sterzi R, Santilli I, Donato MF et al. - Neurologic complications following orthotopic liver transplantation. Transplant Proc 1994; 26:3679-3680. [ Links ]
06. Burkhalter EL, Starzl TE, Van Thiel DH - Severe neurological complications following orthotopic liver transplantation in patients receiving FK 506 and prednisone. J Hepatol 1994;21:572-577. [ Links ]
07. Ghaus N, Bohlega S, Rezeig M - Neurological complications in liver transplantation. J Neurol 2001;248:1042-1048. [ Links ]
08. Bronster DJ, Emre S, Boccagni P et al. - Central nervous system complications in liver transplant recipients: incidence, timing, and long-term follow-up. Clin Transplant 2000;14:1-7. [ Links ]
09. Adams RD, Victor M, Mancall EL - Central pontine myelinolysis: a hitherto undescribed disease occurring in alcoholic and malnourished patients. AMA Arch Neurol Psychiatry 1959;81: 154-172. [ Links ]
10. Starzl TE, Schneck SA, Mazzoni G et al. - Acute neurological complications after liver transplantation with particular reference to intraoperative cerebral air embolus. Ann Surg 1978;187: 236-240. [ Links ]
11. Yu J, Zheng SS, Liang TB et al. - Possible causes of central pontine myelinolysis after liver transplantation. World J Gastroenterol 2004;10:2540-2543. [ Links ]
12. Soupart A, Ngassa M, Decaux G - Therapeutic relowering of the serum sodium in a patient after excessive correction of hyponatremia. Clin Nephrol 1999;51:383-386. [ Links ]
13. Sterns RH, Baer J, Ebersol S et al. - Organic osmolytes in acutehyponatremia. Am J Physiol 1993;264:F833-836. [ Links ]
14. Newell KL, Kleinschmidt-DeMasters BK - Central pontine myelinolysis at autopsy; a twelve year retrospective analysis. J Neurol Sci 1996;142:1394-1399. [ Links ]
15. Brown WD - Osmotic demyelination disorders: central pontine and extrapontine myelinolysis. Curr Opin Neurol 2000;13:691-697. [ Links ]
16. Ashrafian H, Davey P - A review of the causes of central pontine myelinosis: yet another apoptotic illness? Eur J Neurol 2001; 8:103-109. [ Links ]
17. Taneja K, Sabharwal RK, Taneja A et al. - Central pontine myelinolysis in a normonatremic child. Indian Pediatr 1997;34:153-156. [ Links ]
18. Mast H, Gordon PH, Mohr JP et al - Central pontine myelinolysis: clinical syndrome with normal serum sodium. Eur J Med Res 1995; 1:168-170. [ Links ]
19. Ardizzone G, Arrigo A, Schellino MM et al. - Neurological complications of liver cirrhosis and orthotopic liver transplant. Transplant Proc 2006;38:789-792. [ Links ]
20. Grimaldi D, Cavalleri F, Vallone S et al. - Plasmapheresis improves the outcome of central pontine myelinolysis. J Neurol 2005;252: 734-735. [ Links ]
21. Snell DM, Bartley C - Osmotic demyelination syndrome following rapid correction of hyponatraemia. Anaesthesia 2008;63:92-95. [ Links ]
Correspondence to: Submitted em 11
de dezembro de 2008 *
Received from Serviço de Anestesia para Transplante de Órgãos
do Hospital das Clínicas da Universidade Federal de Minas Gerais (HC/UFMG),
Belo Horizonte, MG
Dr. Bruno Salomé de Morais
Rua Donato da Fonseca 213/102 Coração de Jesus
30380-260 Belo Horizonte, MG
Accepted para publicação em 9 de fevereiro de 2009
Submitted em 11
de dezembro de 2008
* Received from Serviço de Anestesia para Transplante de Órgãos do Hospital das Clínicas da Universidade Federal de Minas Gerais (HC/UFMG), Belo Horizonte, MG